ODAN-ERYTHROMYCIN 5 MG — DIN 00641324
ERYTHROMYCIN : 5 MG · ODAN LABORATORIES LTD · OINTMENT · wholesale supply in Canada
Health Canada status: DORMANT
What is ODAN-ERYTHROMYCIN?
ODAN-ERYTHROMYCIN 5 MG contains ERYTHROMYCIN : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 00641324, held by ODAN LABORATORIES LTD, supplied as OINTMENT for OPHTHALMIC administration. Health Canada currently lists it as dormant, status dated 03-Jun-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is ODAN-ERYTHROMYCIN used for?
For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmic neonatorum due to N. gonorrhoeae or C. trachomatis. Erythromycin ophthalmic ointment has also been effective for prevention of neonatal conjunctivitis due to C. trachomatis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Erythromycin cost around the world?
Erythromycin is listed on 11 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 7 | 45 | USD███.██ |
| South Africa | single exit price | 24 | 32 | ZAR███.██ |
| Saudi Arabia | public | 26 | 28 | SAR███.██ |
| Australia | ex-manufacturer | 1 | 4 | AUD███.██ |
| Luxembourg | reimbursement | 4 | 4 | EUR███.██ |
| Bahrain | retail (max) | 2 | 3 | BHD███.██ |
| Czechia | max producer price (ex-factory) | 1 | 2 | CZK███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| Greece | producer price (ex-factory) | 2 | 2 | EUR███.██ |
| Lebanon | public price (USD, Decision 119/1) | 1 | 1 | USD███.██ |
| Romania | max producer price | 1 | 1 | RON███.██ |
124 pack listings across 71 brand entries and 11 price bases, refreshed 08 Sep 2026. Ranges span every Erythromycin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Erythromycin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
9 holders have a Canadian DIN containing Erythromycin, across 9 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PENDOPHARM DIVISION OF PHARMASCIENCE INC | 1 | 1 | PDP-ERYTHROMYCIN | Sourceable in Canada |
| PHARMA STULLN INC. | 1 | 1 | ERYTHROMYCIN | Sourceable in Canada |
| STERI-MED PHARMA INC. | 1 | 1 | ERYTHROMYCIN OPHTHALMIC OINTMENT USP | Sourceable in Canada |
| ELI LILLY CANADA INC | 1 | 0 | ILOTYCIN CRYST OP ONT 0.5% 52 | No marketed DIN |
| EURO-PHARM INTERNATIONAL CANADA INC | 1 | 0 | EURO-ERYTHROMYCIN OPHTHALMIC OINTMENT USP | No marketed DIN |
| MM THERAPEUTICS INC | 1 | 0 | ERYMYCIN OPHTHALMIC OINTMENT 5MG/G | No marketed DIN |
| ODAN LABORATORIES LTD | 1 | 0 | ODAN-ERYTHROMYCIN | No marketed DIN |
| PHARMASCIENCE INC | 1 | 0 | PMS-ERYTHROMYCIN | No marketed DIN |
| RIVEX OPHTHALMICS INC. | 1 | 0 | ERYTHROMYCIN OPHTHALMIC OINTMENT U.S.P. | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 5 MG |
|---|---|
| Dosage form | OINTMENT |
| Route | OPHTHALMIC |
| Pack configuration (monograph) | Single tubes of 3.5 g and unit dose tubes of 1 g in boxes of 50. |
| Storage | Store at room temperature (15°C to 30°C). Protect from freezing. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Erythromycin |
|---|---|
| ATC code | S01AA17 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00641324 |
|---|---|
| DIN (unpadded, as printed on some documents) | 641324 |
| Brand name | ODAN-ERYTHROMYCIN |
| Generic / active ingredient | ERYTHROMYCIN : 5 MG |
| Market authorization holder | ODAN LABORATORIES LTD |
| Health Canada schedule | Prescription |
| ATC code | S01AA17 |
| ATC anatomical main group | S — Sensory organs |
| ATC therapeutic subgroup | S01AA |
| Current status | DORMANT |
| Status date | 03-Jun-2020 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
External ocular infections: Apply directly to infected structure one or more times daily. Neonatal prophylaxis: 0.5 to 1 cm ribbon instilled into each conjunctival sac.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Known hypersensitivity to erythromycin, its derivatives, or any ingredient in the formulation. Infections resistant to the drug (primarily certain Staphylococci).
Warnings and precautions
Risk of drug-resistant bacteria if used without proven/suspected infection. Potential for superinfection (bacteria/fungi) with prolonged use. Remove contact lenses before use.
Is Erythromycin in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by PHARMA STULLN INC. (Tier 3 Drug Shortages About & Resources), last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 9 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ERYTHROMYCIN | 5 MG | OINTMENT | PHARMA STULLN INC. | MARKETED | 02141574 |
| ERYTHROMYCIN OPHTHALMIC OINTMENT USP | 5 MG | OINTMENT | STERI-MED PHARMA INC. | MARKETED | 02326663 |
| PDP-ERYTHROMYCIN | 5 MG | OINTMENT | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | 01912755 |
| ERYMYCIN OPHTHALMIC OINTMENT 5MG/G | 5 MG | OINTMENT | MM THERAPEUTICS INC | CANCELLED POST MARKET | 02237041 |
| ERYTHROMYCIN OPHTHALMIC OINTMENT U.S.P. | 5 MG | OINTMENT | RIVEX OPHTHALMICS INC. | CANCELLED POST MARKET | 02212935 |
| EURO-ERYTHROMYCIN OPHTHALMIC OINTMENT USP | 5 MG | OINTMENT | EURO-PHARM INTERNATIONAL CANADA INC | CANCELLED PRE MARKET | 02460211 |
| ILOTYCIN CRYST OP ONT 0.5% 52 | .5 % | OINTMENT | ELI LILLY CANADA INC | CANCELLED POST MARKET | 00015970 |
| PMS-ERYTHROMYCIN | 5 MG | OINTMENT | PHARMASCIENCE INC | APPROVED | 02492350 |
2 · Same class — other molecules in ATC S01AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Erythromycin | ERYMYCIN OPHTHALMIC OINTMENT 5MG/G · ERYTHROMYCIN · ERYTHROMYCIN OPHTHALMIC OINTMENT U.S.P. · ERYTHROMYCIN OPHTHALMIC OINTMENT USP · +5 more | 9 | 3 | Yes |
| Tobramycin | APO-TOBRAMYCIN · PMS-TOBRAMYCIN 0.3% OPHTHALMIC SOLUTION · SANDOZ TOBRAMYCIN · TOBRAMYCIN OPHTHALMIC SOLUTION USP 0.3% · +2 more | 7 | 3 | Yes |
| Combinations Of Different Antibiotics | DIOSPORIN OINTMENT · EUROSPORIN · NEO BACE OPHTHALMIC OINTMENT · NEOSPORIN OPHTHALMIC OINTMENT · +9 more | 14 | 2 | Yes |
| Fusidic Acid | FUCITHALMIC | 2 | 1 | Yes |
| Gentamicin | ALCOMICIN OPH SOL 3MG/ML · GARAMYCIN OPHTHALMIC DROPS 0.3% · GARAMYCIN OPHTHALMIC OINTMENT 0.3% · GARATEC OPHTHALMIC DPS 5MG/ML · +14 more | 22 | 0 | Not in Canada |
| Chloramphenicol | CEBENICOL OPH LIQ 0.4% · CHLORAMPHENICOL · CHLOROMYCETIN OPH ONT 1% · CHLOROMYCETIN OPH SOLN 0.5% · +12 more | 18 | 0 | Not in Canada |
| Framycetin | SOFRAMYCIN EYE DROPS · SOFRAMYCIN EYE DROPS 0.5% · SOFRAMYCIN EYE DROPS 5MG/ML · SOFRAMYCIN EYE ONT 0.5% · +2 more | 6 | 0 | Not in Canada |
| Tetracycline | ACHROMYCIN ONT OPH 1% · TETRACYCLINE 1% OPHTHALMIC OINTMENT | 2 | 0 | Not in Canada |
| Azithromycin | AZASITE | 2 | 0 | Not in Canada |
| Bacitracin | BACIGUENT OPH ONT 500UNIT/GM | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC S01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| S01AE | Besifloxacin · Ciprofloxacin · Gatifloxacin · Moxifloxacin · Ofloxacin | 25 | 12 |
| S01AD | Ganciclovir · Idoxuridine · Trifluridine | 6 | 1 |
| S01AB | Sulfacetamide · Sulfacetamide, Combinations | 14 | 0 |
| S01AX | Norfloxacin · Sodium Borate | 15 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ODAN-ERYTHROMYCIN called?
The same molecule, Erythromycin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Spectrasone | Latin | South Africa |
| Mayne Pharma Erythromycin | Latin | Australia |
| Omathrocin | Latin | Bahrain, Saudi Arabia |
| Zineryt | Latin | Czechia, South Africa |
| Adco Erythromycin Capsules | Latin | South Africa |
| Erymycin Af | Latin | South Africa |
| ERYTHRODAR | Latin | Saudi Arabia |
| Purmycin Capsules | Latin | South Africa |
| Betamycin | Latin | South Africa |
| EROCIN | Latin | Bahrain |
| Erymycin P | Latin | South Africa |
| Erymycin Pf | Latin | South Africa |
| Erythrocin i v | Latin | South Africa |
| Ilosone | Latin | South Africa |
| Ilotycin T.S | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.